<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37357964</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>229</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.</ArticleTitle><Pagination><StartPage>805</StartPage><EndPage>812</EndPage><MedlinePgn>805-812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiad222</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Novel oral poliovirus vaccine (OPV) type 2 (nOPV2) has been made available for outbreak response under an emergency use listing authorization based on supportive clinical trial data. Since 2021 more than 350 million doses of nOPV2 were used for control of a large outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Nigeria.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a bayesian time-series susceptible-infectious-recovered model, we evaluate the field effectiveness of nOPV2 immunization campaigns in Nigeria compared with campaigns using monovalent OPV type 2 (mOPV2).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that both nOPV2 and mOPV2 campaigns were highly effective in reducing transmission of cVDPV2, on average reducing the susceptible population by 42% (95% confidence interval, 28-54%) and 38% (20-51%) per campaign, respectively, which were indistinguishable from each other in this analysis (relative effect, 1.1 [.7-1.9]). Impact was found to vary across areas and between immunization campaigns.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results are consistent with the comparable individual immunogenicity of nOPV2 and mOPV2 found in clinical trials but also suggest that outbreak response campaigns may have small impacts in some areas requiring more campaigns than are suggested in current outbreak response procedures.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voorman</LastName><ForeName>Arend</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6242-7796</Identifier><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Hil</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuaib</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamu</LastName><ForeName>Usman S</ForeName><Initials>US</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korir</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>World Health Organization, Nigeria Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erbeto</LastName><ForeName>Tesfaye</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>World Health Organization, Nigeria Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-8395-2001</Identifier><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okiror</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">mass vaccination</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">susceptible infected recovered models</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. A. V., H. L., A. S. B., and S. O. are employed by the Bill &amp; Melinda Gates Foundation. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37357964</ArticleId><ArticleId IdType="pmc">PMC10938209</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad222</ArticleId><ArticleId IdType="pii">7207511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garon &#xa0;J, Seib &#xa0;K, Orenstein &#xa0;WA, et al. &#xa0;Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines &#xa0;2016; 15:693&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin &#xa0;GR, O&#x2019;Reilly &#xa0;KM, Grassly &#xa0;NC, et al. &#xa0;Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccine. Science &#xa0;2020; 368:401&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin &#xa0;G, Peak &#xa0;C, Eisenhawer &#xa0;M, et al. &#xa0;Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine &#xa0;2022; 41 (suppl 1):A122&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin &#xa0;J, Burns &#xa0;CC, Jorba &#xa0;J, et al. &#xa0;Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing&#x2014;worldwide, March&#x2013;October 2021. MMWR Morb Mortal Wkly Rep &#xa0;2022; 71:786&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay &#xa0;AS, Zipursky &#xa0;S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect Dis &#xa0;2023; 23:e67&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">36162417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill &#xa0;M, Bandyopadhyay &#xa0;AS, Pollard &#xa0;AJ. Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet &#xa0;2022; 400:713&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35988575</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster &#xa0;I, Leroux-Roels &#xa0;I, Bandyopadhyay &#xa0;AS, et al. &#xa0;Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet &#xa0;2021; 397:39&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-Llorens &#xa0;X, Bandyopadhyay &#xa0;AS, Gast &#xa0;C, et al. &#xa0;Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet &#xa0;2021; 397:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme &#xa0;P, De Coster &#xa0;I, Bandyopadhyay &#xa0;AS, et al. &#xa0;The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet &#xa0;2019; 394:148&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca &#xa0;PA, Wright &#xa0;PF, John &#xa0;TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis &#xa0;1990; 13:926&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly &#xa0;NC, Wenger &#xa0;J, Durrani &#xa0;S, et al. &#xa0;Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet &#xa0;2007; 369:1356&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448821</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins &#xa0;HE, Aylward &#xa0;RB, Gasasira &#xa0;A, et al. &#xa0;Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med &#xa0;2008; 359:1666&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy &#xa0;SB, Macklin &#xa0;GR, Mason Ross &#xa0;G, et al. &#xa0;Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey. Lancet Glob Health &#xa0;2023; 11:e917&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187988</ArticleId><ArticleId IdType="pubmed">37202026</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare &#xa0;M, Selinger &#xa0;C, McCarthy &#xa0;KA, Eckhoff &#xa0;PA, Chabot-Couture &#xa0;G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. PLoS Biol &#xa0;2018; 16:e2002468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942853</ArticleId><ArticleId IdType="pubmed">29702638</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyesh-Melnick &#xa0;M, Melnick &#xa0;JL, Rawls &#xa0;WE, et al. &#xa0;Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol &#xa0;1967; 86:112&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">4378110</ArticleId></ArticleIdList></Reference><Reference><Citation>Gast &#xa0;C, Bandyopadhyay &#xa0;AS, S&#xe1;ez-Llorens &#xa0;X, et al. &#xa0;Fecal shedding of 2 novel live attenuated oral poliovirus type 2 vaccine candidates by healthy infants administered bivalent oral poliovirus vaccine/inactivated poliovirus vaccine: 2 randomized clinical trials. J Infect Dis &#xa0;2021; 226:852&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470102</ArticleId><ArticleId IdType="pubmed">34610135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson &#xa0;AL, Zaman &#xa0;K, Hoque &#xa0;M, et al. &#xa0;Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis doi:10.1016/S1473-3099(23)00139-1. Published 10 May 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00139-1</ArticleId><ArticleId IdType="pmc">PMC10503264</ArticleId><ArticleId IdType="pubmed">37178706</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns &#xa0;CC, Shaw &#xa0;J, Jorba &#xa0;J, et al. &#xa0;Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in Northern Nigeria. J Virol &#xa0;2013; 87:4907&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamage &#xa0;D, Mach &#xa0;O, Palihawadana &#xa0;P, et al. &#xa0;Boosting of mucosal immunity after fractional-dose inactivated poliovirus vaccine. J Infect Dis &#xa0;2018; 218:1876&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161111</ArticleId><ArticleId IdType="pubmed">29982532</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman &#xa0;A, Lyons &#xa0;H, Bennette &#xa0;C, et al. &#xa0;Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine &#xa0;2022; 41 &#xa0;Suppl 1:A85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10973941</ArticleId><ArticleId IdType="pubmed">35339308</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens &#xa0;FR, Gaughan &#xa0;AE, Linard &#xa0;C, Tatem &#xa0;AJ. Disaggregating census data for population mapping using random forests with remotely-sensed and ancillary data. PLoS One &#xa0;2015; 10:e0107042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331277</ArticleId><ArticleId IdType="pubmed">25689585</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakkar &#xa0;N, Gilani &#xa0;SSA, Hasan &#xa0;Q, McCarthy &#xa0;KA. Decreasing measles burden by optimizing campaign timing. Proc Natl Acad Sci U S A &#xa0;2019; 116:11069&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561209</ArticleId><ArticleId IdType="pubmed">31085656</ArticleId></ArticleIdList></Reference><Reference><Citation>

Dong &#xa0;TQ, Wakefield &#xa0;J. Estimating efficacy of measles supplementary immunization activities via discrete-time modeling of disease incidence time series. arXiv &#xa0;[Preprint: not peer reviewed]. 17 October 2020. Available from: &#xa0;https://arxiv.org/abs/2010.08875.</Citation></Reference><Reference><Citation>McCarthy &#xa0;KA, Chabot-Couture &#xa0;G, Shuaib &#xa0;F. A spatial model of wild poliovirus type 1 in Kano State, Nigeria: calibration and assessment of elimination probability. BMC Infect Dis &#xa0;2016; 16:521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5041410</ArticleId><ArticleId IdType="pubmed">27681708</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander &#xa0;JP, Gary &#xa0;HE, Pallansch &#xa0;MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis &#xa0;1997; 175:S176&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203713</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly &#xa0;KM, Durry &#xa0;E, ul Islam &#xa0;O, et al. &#xa0;The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001&#x2013;11: a retrospective analysis. Lancet &#xa0;2012; 380:491&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418593</ArticleId><ArticleId IdType="pubmed">22766207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>